Cargando…
Exploiting LRRC15 as a Novel Therapeutic Target in Cancer
Abundant fibrotic stroma is a typical feature of most solid tumors, and stromal activation promotes oncogenesis, therapy resistance, and metastatic dissemination of cancer cells. Therefore, targeting the tumor stroma in combination with standard-of-care therapies has become a promising therapeutic s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064950/ https://www.ncbi.nlm.nih.gov/pubmed/35260879 http://dx.doi.org/10.1158/0008-5472.CAN-21-3734 |
_version_ | 1784699483430322176 |
---|---|
author | Ray, Upasana Pathoulas, Christopher L. Thirusangu, Prabhu Purcell, James W. Kannan, Nagarajan Shridhar, Viji |
author_facet | Ray, Upasana Pathoulas, Christopher L. Thirusangu, Prabhu Purcell, James W. Kannan, Nagarajan Shridhar, Viji |
author_sort | Ray, Upasana |
collection | PubMed |
description | Abundant fibrotic stroma is a typical feature of most solid tumors, and stromal activation promotes oncogenesis, therapy resistance, and metastatic dissemination of cancer cells. Therefore, targeting the tumor stroma in combination with standard-of-care therapies has become a promising therapeutic strategy in recent years. The leucine-rich repeat-containing protein 15 (LRRC15) is involved in cell–cell and cell–matrix interactions and came into focus as a promising anticancer target owing to its overexpression in mesenchymal-derived tumors such as sarcoma, glioblastoma, and melanoma and in cancer-associated fibroblasts in the microenvironment of breast, head and neck, lung, and pancreatic tumors. Effective targeting of LRRC15 using specific antibody–drug conjugates (ADC) has the potential to improve the outcome of patients with LRRC15-positive (LRRC15(+)) cancers of mesenchymal origin or stromal desmoplasia. Moreover, LRRC15 expression may serve as a predictive biomarker that could be utilized in the preclinical assessment of cancer patients to support personalized clinical outcomes. This review focuses on the role of LRRC15 in cancer, including clinical trials involving LRRC15-targeted therapies, such as the ABBV-085 ADC for patients with LRRC15(+) tumors. This review spans perceived knowledge gaps and highlights the clinical avenues that need to be explored to provide better therapeutic outcomes in patients. |
format | Online Article Text |
id | pubmed-9064950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-90649502022-05-03 Exploiting LRRC15 as a Novel Therapeutic Target in Cancer Ray, Upasana Pathoulas, Christopher L. Thirusangu, Prabhu Purcell, James W. Kannan, Nagarajan Shridhar, Viji Cancer Res Reviews Abundant fibrotic stroma is a typical feature of most solid tumors, and stromal activation promotes oncogenesis, therapy resistance, and metastatic dissemination of cancer cells. Therefore, targeting the tumor stroma in combination with standard-of-care therapies has become a promising therapeutic strategy in recent years. The leucine-rich repeat-containing protein 15 (LRRC15) is involved in cell–cell and cell–matrix interactions and came into focus as a promising anticancer target owing to its overexpression in mesenchymal-derived tumors such as sarcoma, glioblastoma, and melanoma and in cancer-associated fibroblasts in the microenvironment of breast, head and neck, lung, and pancreatic tumors. Effective targeting of LRRC15 using specific antibody–drug conjugates (ADC) has the potential to improve the outcome of patients with LRRC15-positive (LRRC15(+)) cancers of mesenchymal origin or stromal desmoplasia. Moreover, LRRC15 expression may serve as a predictive biomarker that could be utilized in the preclinical assessment of cancer patients to support personalized clinical outcomes. This review focuses on the role of LRRC15 in cancer, including clinical trials involving LRRC15-targeted therapies, such as the ABBV-085 ADC for patients with LRRC15(+) tumors. This review spans perceived knowledge gaps and highlights the clinical avenues that need to be explored to provide better therapeutic outcomes in patients. American Association for Cancer Research 2022-05-03 2022-03-08 /pmc/articles/PMC9064950/ /pubmed/35260879 http://dx.doi.org/10.1158/0008-5472.CAN-21-3734 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License. |
spellingShingle | Reviews Ray, Upasana Pathoulas, Christopher L. Thirusangu, Prabhu Purcell, James W. Kannan, Nagarajan Shridhar, Viji Exploiting LRRC15 as a Novel Therapeutic Target in Cancer |
title | Exploiting LRRC15 as a Novel Therapeutic Target in Cancer |
title_full | Exploiting LRRC15 as a Novel Therapeutic Target in Cancer |
title_fullStr | Exploiting LRRC15 as a Novel Therapeutic Target in Cancer |
title_full_unstemmed | Exploiting LRRC15 as a Novel Therapeutic Target in Cancer |
title_short | Exploiting LRRC15 as a Novel Therapeutic Target in Cancer |
title_sort | exploiting lrrc15 as a novel therapeutic target in cancer |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064950/ https://www.ncbi.nlm.nih.gov/pubmed/35260879 http://dx.doi.org/10.1158/0008-5472.CAN-21-3734 |
work_keys_str_mv | AT rayupasana exploitinglrrc15asanoveltherapeutictargetincancer AT pathoulaschristopherl exploitinglrrc15asanoveltherapeutictargetincancer AT thirusanguprabhu exploitinglrrc15asanoveltherapeutictargetincancer AT purcelljamesw exploitinglrrc15asanoveltherapeutictargetincancer AT kannannagarajan exploitinglrrc15asanoveltherapeutictargetincancer AT shridharviji exploitinglrrc15asanoveltherapeutictargetincancer |